Belldegrun A - Search Results

1

Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma.

Sargent ER, Gomella LG, Belldegrun A, Linehan WM, Kasid A. Sargent ER, et al. Among authors: belldegrun a. J Urol. 1989 Nov;142(5):1364-8. doi: 10.1016/s0022-5347(17)39100-0. J Urol. 1989. PMID: 2810532

2

Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid.

Belldegrun A, Kasid A, Uppenkamp M, Rosenberg SA. Belldegrun A, et al. Cancer Immunol Immunother. 1990;31(1):1-10. doi: 10.1007/BF01742489. Cancer Immunol Immunother. 1990. PMID: 1968360 Free PMC article.

3

Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy.

Belldegrun A, Webb DE, Austin HA 3rd, Steinberg SM, Linehan WM, Rosenberg SA. Belldegrun A, et al. J Urol. 1989 Mar;141(3):499-503. doi: 10.1016/s0022-5347(17)40872-x. J Urol. 1989. PMID: 2783983

4

Superficial bladder cancer: the role of interferon-alpha.

Belldegrun AS, Franklin JR, O'Donnell MA, Gomella LG, Klein E, Neri R, Nseyo UO, Ratliff TL, Williams RD. Belldegrun AS, et al. J Urol. 1998 Jun;159(6):1793-801. doi: 10.1016/S0022-5347(01)63160-4. J Urol. 1998. PMID: 9598463 Review.

5

Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy.

Belldegrun A, Kasid A, Uppenkamp M, Topalian SL, Rosenberg SA. Belldegrun A, et al. J Immunol. 1989 Jun 15;142(12):4520-6. J Immunol. 1989. PMID: 2723437

6

Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer.

Webb DE, Austin HA 3rd, Belldegrun A, Vaughan E, Linehan WM, Rosenberg SA. Webb DE, et al. Among authors: belldegrun a. Clin Nephrol. 1988 Sep;30(3):141-5. Clin Nephrol. 1988. PMID: 3263237

7

Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer.

Belldegrun A, Uppenkamp I, Rosenberg SA. Belldegrun A, et al. J Urol. 1988 Jan;139(1):150-5. doi: 10.1016/s0022-5347(17)42342-1. J Urol. 1988. PMID: 3257274

8

Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome.

Zisman A, Pantuck AJ, Chao D, Dorey F, Said JW, Gitlitz BJ, de Kernion JB, Figlin RA, Belldegrun AS. Zisman A, et al. Among authors: belldegrun as. J Urol. 2001 Jul;166(1):54-8. J Urol. 2001. PMID: 11435822

9

Incidental renal tumors.

Pantuck AJ, Zisman A, Rauch MK, Belldegrun A. Pantuck AJ, et al. Among authors: belldegrun a. Urology. 2000 Aug 1;56(2):190-6. doi: 10.1016/s0090-4295(00)00655-5. Urology. 2000. PMID: 10925076 Review. No abstract available.

10

Gene and immune therapy for renal cell carcinoma.

Pantuck AJ, Zisman A, Belldegrun A. Pantuck AJ, et al. Among authors: belldegrun a. Int J Urol. 2001 Jul;8(7):S1-4. doi: 10.1046/j.1442-2042.2001.00326.x. Int J Urol. 2001. PMID: 11442668 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

421 results

Search Page